New Eye Drop Formulation Based on Desonide and Xanthan Gum in Dry Eye Disease: Nonclinical Studies DOI Creative Commons

Santa Viola,

Luca Rosario La Rosa,

Giuseppe De Pasquale

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 235 - 235

Опубликована: Фев. 12, 2025

Background/Objectives: A novel ophthalmic formulation, XanterDES, containing 0.2% xanthan gum and 0.025% desonide sodium phosphate (DES), was developed to alleviate ocular surface discomfort irritation. This study aimed evaluate its pharmacodynamic properties characterize rheological behavior mucoadhesive characteristics, compared another formulation hyaluronic acid 0.001% hydrocortisone (HYD). Methods: rabbit (New Zealand White) model of LPS-induced uveitis used test different concentrations DES on markers inflammation. The efficacy XanterDES HYD induced dry eye evaluated by assessing tear volume corneal damage in C57BL/6 mice exposed a controlled environmental chamber. were assessed using HAAKE RheoStress RS600 rheometer TA-XT2 texture analyzer, respectively. Results: In the model, unlike 0.25%, low concentration showed significant inhibitory activity localized effectively reduced edema. demonstrated superior HYD, preventing both reduction damage. also pseudoplastic enhanced HYD. Conclusions: ancillary anti-inflammatory effects dose combined with biophysical are supportive favorable therapeutic profile, promoting maintenance or restoration homeostasis while minimizing risk adverse typically associated standard-dose corticosteroids. comparison low-dose corticosteroid highlights superiority performance.

Язык: Английский

New Eye Drop Formulation Based on Desonide and Xanthan Gum in Dry Eye Disease: Nonclinical Studies DOI Creative Commons

Santa Viola,

Luca Rosario La Rosa,

Giuseppe De Pasquale

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 235 - 235

Опубликована: Фев. 12, 2025

Background/Objectives: A novel ophthalmic formulation, XanterDES, containing 0.2% xanthan gum and 0.025% desonide sodium phosphate (DES), was developed to alleviate ocular surface discomfort irritation. This study aimed evaluate its pharmacodynamic properties characterize rheological behavior mucoadhesive characteristics, compared another formulation hyaluronic acid 0.001% hydrocortisone (HYD). Methods: rabbit (New Zealand White) model of LPS-induced uveitis used test different concentrations DES on markers inflammation. The efficacy XanterDES HYD induced dry eye evaluated by assessing tear volume corneal damage in C57BL/6 mice exposed a controlled environmental chamber. were assessed using HAAKE RheoStress RS600 rheometer TA-XT2 texture analyzer, respectively. Results: In the model, unlike 0.25%, low concentration showed significant inhibitory activity localized effectively reduced edema. demonstrated superior HYD, preventing both reduction damage. also pseudoplastic enhanced HYD. Conclusions: ancillary anti-inflammatory effects dose combined with biophysical are supportive favorable therapeutic profile, promoting maintenance or restoration homeostasis while minimizing risk adverse typically associated standard-dose corticosteroids. comparison low-dose corticosteroid highlights superiority performance.

Язык: Английский

Процитировано

0